TELO Key Statistics, Chart & Performance
The current stock price of TELO is 1.15 USD. In the past month the price decreased by -23.55%. In the past year, price decreased by -74.37%.
TELO Technical Analysis
TELO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TELO. TELO has a great financial health rating, but its profitability evaluates not so good.
TELO Financial Highlights
Over the last trailing twelve months TELO reported a non-GAAP Earnings per Share(EPS) of -0.37. The EPS increased by 64.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -151.99% | ||
| ROE | -161.2% | ||
| Debt/Equity | 0 |
TELO Forecast & Estimates
null analysts have analysed TELO and the average price target is 15.81 USD. This implies a price increase of 1274.78% is expected in the next year compared to the current price of 1.15.
TELO Ownership
TELO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.53 | 965.082B | ||
| JNJ | JOHNSON & JOHNSON | 20.76 | 572.907B | ||
| MRK | MERCK & CO. INC. | 22.54 | 297.222B | ||
| PFE | PFIZER INC | 9.06 | 150.614B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.19 | 121.168B | ||
| ZTS | ZOETIS INC | 18.6 | 55.849B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.61 | 25.456B | ||
| VTRS | VIATRIS INC | 5.78 | 16.516B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.9 | 12.079B | ||
| AXSM | AXSOME THERAPEUTICS INC | 223.48 | 9.116B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TELO
Company Profile
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Company Info
TELOMIR PHARMACEUTICALS INC
900 West Platt Street, Suite 200
Tampa FLORIDA US
Employees: 0
Phone: 18138642562
TELOMIR PHARMACEUTICALS INC / TELO FAQ
Can you describe the business of TELOMIR PHARMACEUTICALS INC?
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company, which focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The company is headquartered in Tampa, Florida and currently employs 0 full-time employees. The company went IPO on 2024-02-09. The firm is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. The company is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. The company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
What is the stock price of TELOMIR PHARMACEUTICALS INC today?
The current stock price of TELO is 1.15 USD. The price increased by 2.68% in the last trading session.
Does TELO stock pay dividends?
TELO does not pay a dividend.
What is the ChartMill technical and fundamental rating of TELO stock?
TELO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for TELO stock?
TELOMIR PHARMACEUTICALS INC (TELO) currently has 0 employees.
When does TELOMIR PHARMACEUTICALS INC (TELO) report earnings?
TELOMIR PHARMACEUTICALS INC (TELO) will report earnings on 2026-05-12.
What is the ownership structure of TELOMIR PHARMACEUTICALS INC (TELO)?
You can find the ownership structure of TELOMIR PHARMACEUTICALS INC (TELO) on the Ownership tab.